Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee advances AB 1103 to expedite state review of controlled-substance clinical research
Summary
AB 1103 would create an expedited review process for the Research Advisory Panel of California (RAPC) to reduce approval delays for federally authorized clinical trials involving schedule I and II substances, sponsors said. Veterans and treatment advocates urged the change citing delayed research and care; no formal opposition was recorded.
Assemblymember Padilla presented AB 1103, which would authorize an expedited review process for the Research Advisory Panel of California (RAPC) to approve federally sanctioned drug trials and clinical research involving schedule I and II controlled substances. The bill is intended to align state review procedures with federal approvals and reduce…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
